Close
Almac
Achema middle east

News

Russia to present Sputnik V vaccine against coronavirus at United Nations

Russia's permanent mission to the UN and the Health Ministry will hold a presentation, which will provide detailed information on the Russian vaccine against the novel coronavirus disease (COVID-19), mission spokesman Fyodor Strzhizhovsky told Sputnik. During a speech at the...

Algernon completes patient enrollment in phase 2b/3 study of Ifenprodil to treat COVID-19

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that the final patient has been enrolled in its multinational phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from...

Sterling announces strategic investment in ADC Biotechnology

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions (Sterling), has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK based biotechnology company specialising in antibody drug conjugates. The partnership will see Sterling make a significant...

FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States FDA has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome (ARDS) due to COVID-19 infection. Fast Track...

Janssen Inc Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada

Janssen Inc. the pharmaceutical companies of Johnson & Johnson, has initiated a rolling submission with Health Canada for its investigational single-dose vaccine candidate for the prevention of COVID-19. Health Canada announced a rolling review of the investigational single-dose Janssen COVID-19...

EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2

EMA has received an application for conditional marketing authorisation (CMA) for BNT162b2, a COVID?19 mRNA vaccine developed by BioNTech and Pfizer. The assessment of BNT162b2 will proceed under an accelerated timeline. An opinion on the marketing authorisation could be...

Biogen partners with Sage Therapeutics on depression, movement disorder drugs

Biogen entered into an agreement to jointly develop and commercialise Sage Therapeutics' zuranolone for major depressive disorder (MDD) and postpartum depression (PDD), as well as SAGE-324 for essential tremor, the companies announced Friday. Under the deal, Biogen will pay...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »